Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of mavacamten in healthy volunteers
NCT02356289Phase 1Completed
- Sponsor
- MyoKardia
- Start
- Jan 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing MYK-461 with Placebo (2 arms). Primary endpoint: Incidence of adverse events at 28 Days. Started Jan 2015; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT02356289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356289.